Respiratory Effects of Treatment with a Glucagon-Like Peptide-1 Receptor Agonist in Patients Suffering from Obesity and Chronic Obstructive Pulmonary Disease.

Ayse Dudu Altintas DoganOle HilbergSøren HessTorben Tranborg JensenElse Marie BladbjergClaus Bogh Juhl

Published in: International journal of chronic obstructive pulmonary disease (2022)

In patients suffering from obesity and COPD, 40 weeks of treatment with liraglutide improved some measures of pulmonary function. Our study suggests that liraglutide at 3.0 mg may be appropriate treatment in patients with obesity and COPD.

Keyphrases

chronic obstructive pulmonary disease
end stage renal disease
metabolic syndrome
insulin resistance
type diabetes
ejection fraction
weight loss
newly diagnosed
peritoneal dialysis
weight gain
skeletal muscle
patient reported outcomes
combination therapy